Piribedil-induced sleep attacks in patients without Parkinson disease: a case series.
Identifieur interne : 000936 ( PubMed/Curation ); précédent : 000935; suivant : 000937Piribedil-induced sleep attacks in patients without Parkinson disease: a case series.
Auteurs : Aurore Gouraud [France] ; Anne Millaret ; Jacques Descotes ; Thierry VialSource :
- Clinical neuropharmacology [ 1537-162X ]
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antiparkinson Agents (adverse effects), Databases, Factual, Female, Humans, Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Piribedil (adverse effects), Sleep Wake Disorders (chemically induced), Sleep Wake Disorders (physiopathology).
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Piribedil.
- chemically induced : Sleep Wake Disorders.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease, Sleep Wake Disorders.
- Aged, Aged, 80 and over, Databases, Factual, Female, Humans, Male, Middle Aged.
Abstract
Sleep attacks were initially described in 1999 in patients with Parkinson disease (PD) treated by dopamine agonists (DAs). Because the respective role of DAs or PD-induced excessive daytime sleepiness is still unclear, reports of sleep attacks in non-PD patients treated with DA would support the specific role of these drugs. Piribedil, a nonergot dopamine D2/D3 agonist with alpha(2)-noradrenergic properties, is indicated in the treatment of PD as well as in patients with circulatory disorders. After a spontaneous report of sleep attack associated with piribedil use in a non-PD patient, we reviewed other cases from the French pharmacovigilance database.
DOI: 10.1097/WNF.0b013e31821f0d8b
PubMed: 21586915
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000976
Links to Exploration step
pubmed:21586915Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Piribedil-induced sleep attacks in patients without Parkinson disease: a case series.</title><author><name sortKey="Gouraud, Aurore" sort="Gouraud, Aurore" uniqKey="Gouraud A" first="Aurore" last="Gouraud">Aurore Gouraud</name><affiliation wicri:level="1"><nlm:affiliation>Poison Center and Pharmacovigilance Department, Lyon University Hospitals, Lyon, France. aurore.gouraud@chu-lyon.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Poison Center and Pharmacovigilance Department, Lyon University Hospitals, Lyon</wicri:regionArea></affiliation></author><author><name sortKey="Millaret, Anne" sort="Millaret, Anne" uniqKey="Millaret A" first="Anne" last="Millaret">Anne Millaret</name></author><author><name sortKey="Descotes, Jacques" sort="Descotes, Jacques" uniqKey="Descotes J" first="Jacques" last="Descotes">Jacques Descotes</name></author><author><name sortKey="Vial, Thierry" sort="Vial, Thierry" uniqKey="Vial T" first="Thierry" last="Vial">Thierry Vial</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2011 May-Jun</MedlineDate></PubDate></date><idno type="RBID">pubmed:21586915</idno><idno type="pmid">21586915</idno><idno type="doi">10.1097/WNF.0b013e31821f0d8b</idno><idno type="wicri:Area/PubMed/Corpus">000976</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000976</idno><idno type="wicri:Area/PubMed/Curation">000936</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000936</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Piribedil-induced sleep attacks in patients without Parkinson disease: a case series.</title><author><name sortKey="Gouraud, Aurore" sort="Gouraud, Aurore" uniqKey="Gouraud A" first="Aurore" last="Gouraud">Aurore Gouraud</name><affiliation wicri:level="1"><nlm:affiliation>Poison Center and Pharmacovigilance Department, Lyon University Hospitals, Lyon, France. aurore.gouraud@chu-lyon.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Poison Center and Pharmacovigilance Department, Lyon University Hospitals, Lyon</wicri:regionArea></affiliation></author><author><name sortKey="Millaret, Anne" sort="Millaret, Anne" uniqKey="Millaret A" first="Anne" last="Millaret">Anne Millaret</name></author><author><name sortKey="Descotes, Jacques" sort="Descotes, Jacques" uniqKey="Descotes J" first="Jacques" last="Descotes">Jacques Descotes</name></author><author><name sortKey="Vial, Thierry" sort="Vial, Thierry" uniqKey="Vial T" first="Thierry" last="Vial">Thierry Vial</name></author></analytic><series><title level="j">Clinical neuropharmacology</title><idno type="eISSN">1537-162X</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (adverse effects)</term><term>Databases, Factual</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Piribedil (adverse effects)</term><term>Sleep Wake Disorders (chemically induced)</term><term>Sleep Wake Disorders (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Piribedil</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Sleep Wake Disorders</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term><term>Sleep Wake Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Databases, Factual</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sleep attacks were initially described in 1999 in patients with Parkinson disease (PD) treated by dopamine agonists (DAs). Because the respective role of DAs or PD-induced excessive daytime sleepiness is still unclear, reports of sleep attacks in non-PD patients treated with DA would support the specific role of these drugs. Piribedil, a nonergot dopamine D2/D3 agonist with alpha(2)-noradrenergic properties, is indicated in the treatment of PD as well as in patients with circulatory disorders. After a spontaneous report of sleep attack associated with piribedil use in a non-PD patient, we reviewed other cases from the French pharmacovigilance database.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21586915</PMID><DateCreated><Year>2011</Year><Month>05</Month><Day>18</Day></DateCreated><DateCompleted><Year>2012</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-162X</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>3</Issue><PubDate><MedlineDate>2011 May-Jun</MedlineDate></PubDate></JournalIssue><Title>Clinical neuropharmacology</Title><ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>Piribedil-induced sleep attacks in patients without Parkinson disease: a case series.</ArticleTitle><Pagination><MedlinePgn>104-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/WNF.0b013e31821f0d8b</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sleep attacks were initially described in 1999 in patients with Parkinson disease (PD) treated by dopamine agonists (DAs). Because the respective role of DAs or PD-induced excessive daytime sleepiness is still unclear, reports of sleep attacks in non-PD patients treated with DA would support the specific role of these drugs. Piribedil, a nonergot dopamine D2/D3 agonist with alpha(2)-noradrenergic properties, is indicated in the treatment of PD as well as in patients with circulatory disorders. After a spontaneous report of sleep attack associated with piribedil use in a non-PD patient, we reviewed other cases from the French pharmacovigilance database.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Cases of piribedil associated with sleep attacks recorded between 1988 and December 2008 were identified in the French Pharmacovigilance database. Cases were retained for analysis only if patients were treated for conditions other than PD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, a total of 35 cases of piribedil-induced sleep disorders were retrieved, and 7 cases suggestive of sleep attacks were retained for analysis. The mean time to onset after starting piribedil was 2.5 days. Piribedil was the only suspected drug in all but 1 patient. Complete recovery was noticed after piribedil discontinuation in all patients, and recurrence of symptoms was observed after piribedil reintroduction in 1 patient.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our series suggests that piribedil may be associated with sleep attack disorders independently of the treated disease and supports the prominent role of DAs in sleep disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gouraud</LastName><ForeName>Aurore</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Poison Center and Pharmacovigilance Department, Lyon University Hospitals, Lyon, France. aurore.gouraud@chu-lyon.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millaret</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Descotes</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Vial</LastName><ForeName>Thierry</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><CollectiveName>French Association of Regional Pharmacovigilance Centres</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Neuropharmacol</MedlineTA><NlmUniqueID>7607910</NlmUniqueID><ISSNLinking>0362-5664</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>DO22K1PRDJ</RegistryNumber><NameOfSubstance UI="D010891">Piribedil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010891" MajorTopicYN="N">Piribedil</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21586915</ArticleId><ArticleId IdType="doi">10.1097/WNF.0b013e31821f0d8b</ArticleId><ArticleId IdType="pii">00002826-201105000-00003</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000936 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000936 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:21586915
|texte= Piribedil-induced sleep attacks in patients without Parkinson disease: a case series.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:21586915" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |